ClinicalTrials.gg
Not yet recruitingNCT07919028Updated Nov 5, 2026

A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006)

A Phase 1 interventional study of MK-7602 and Pyronaridine in Healthy, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Updated Nov 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

MK-7602 is a new medicine that is being studied to treat malaria. Malaria is a disease caused by a parasite that spreads to people through mosquito bites. Symptoms of malaria include fever, chills, and flu-like illness. If malaria is not treated, some people can have serious problems that can be deadly.

The goal of this trial is to learn what happens to MK-7602 in a person's body over time (a pharmacokinetic or PK trial). Researchers will compare what happens to MK-7602 in people's blood when it is taken alone (Period 1) and in combination with another medicine called pyronaridine (Period 2). Researchers also want to learn about the safety of MK-7602 taken with and without pyronaridine and if people tolerate them.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is in good health
  • Has a (BMI) between 18 and 32 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has history of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of cancer ()
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Period 1: MK-7602

    Participants will receive an oral dose of MK-7602 once daily on Days 1, 2, and 3 of Period 1.

    Drug: MK-7602

  • Experimental
    Period 2: MK-7602 + Pyronaridine

    Participants will receive oral doses of MK-7602 and pyronaridine once daily on Days 1, 2, and 3 of Period 2.

    Drug: MK-7602 · Drug: Pyronaridine

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time 0 to the Next Dosing Interval (AUC0-tau) of MK-7602

    Blood samples will be collected to determine the AUC0-tau of MK-7602 with and without pyronaridine.

    Time frame: At designated timepoints (up to approximately 21 days)

  2. Maximum Plasma Concentration (Cmax) of MK-7602

    Blood samples will be collected to determine the Cmax of MK-7602 with and without pyronaridine.

    Time frame: At designated timepoints (up to approximately 21 days)

  3. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 2 months

  4. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 20 days

Secondary outcomes

  1. AUC0-tau of MK-7602

    Blood samples will be collected to determine the AUC0-tau of MK-7602 with and without pyronaridine.

    Time frame: At designated timepoints (up to approximately 19 days)

  2. Cmax of MK-7602

    Blood samples will be collected to determine the Cmax of MK-7602 with and without pyronaridine.

    Time frame: At designated timepoints (up to approximately 19 days)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Apr 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 5, 2026
StartEst.
Jan 4, 2027
Primary completionEst.
Apr 5, 2027
CompletionEst.
Apr 5, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07919028
Responsible party
Sponsor
First posted
Nov 5, 2026
Start date
Jan 4, 2027 (estimated)
Primary completion
Apr 5, 2027 (estimated)
Completion
Apr 5, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MK-7602 · Pyronaridine

Start the discussion